Alemtuzumab in refractory Sézary syndrome
An. bras. dermatol
;
91(5): 642-644, Sept.-Oct. 2016. graf
Artigo
em Inglês
| LILACS
| ID: biblio-827761
ABSTRACT
Abstract Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refractory Sézary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response. The treatment was discontinued after 4 months due to adverse effects, with the patient showing a sustained response without disease progression after 13 months of follow-up.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Neoplasias Cutâneas
/
Síndrome de Sézary
/
Anticorpos Monoclonais Humanizados
/
Antineoplásicos
Limite:
Idoso
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
An. bras. dermatol
Assunto da revista:
Dermatologia
Ano de publicação:
2016
Tipo de documento:
Artigo
País de afiliação:
Espanha
Instituição/País de afiliação:
Hospital Universitario Reina Sofía/ES
Similares
MEDLINE
...
LILACS
LIS